StockWatch
·

Research Reports

19 Aug 2026
RUBICONRubicon Research Ltd

Margins are genuine, stock is fully valued — Rubicon delivers but leaves no margin for error

specialty pharma · margin expansion · facility ramp-up

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
RUBICONRubicon Research Ltd

Strong growth & margin expansion via specialty shift; new capacity unlocking next phase

specialty portfolio · manufacturing footprint · R&D productivity

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
KPLKwality Pharmaceuticals Ltd

Growth intact, but sequential deceleration signals headwinds ahead

generics · injectables · registrations

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
KPLKwality Pharmaceuticals Ltd

Growth tracked, but catalysts deferred — FY30 ambition clear

registrations · oncology-delay · biosimilar

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
PPLPHARMAPiramal Pharma Ltd

Margin beat masked by net loss; execution sound, scale pending

EBITDA expansion · ADC platform · overseas utilization

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
GLANDGland Pharma Ltd

The Reported Beat Masks Steady Execution—and a Capacity Gate

CDMO growth · capacity constraints · forex tailwind

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
GLANDGland Pharma Ltd

Beat FY27 guidance, large CDMO deal; capacity constraints cap near-term

CDMO momentum · contract wins · capacity expansion

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
GLENMARKGLENMARK PHARMACEUTICALS LTD.

Strong Q1 growth, margin compressed by geopolitical costs

respiratory launches · oncology ramp · cost pressures

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
SYNGENESyngene International Ltd

Librela Cliff and FX Loss Mask a Credible Reset — Proof Points Are Late

Librela destocking · CDMO pivot · margin compression

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
18 Aug 2026
SYNGENESyngene International Ltd

Zoetis loss cripples Q1; new strategy unproven but credible

Librela destocking · CDMO pivot · customer concentration

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
TORNTPHARMTORRENT PHARMACEUTICALS LTD.

Strong Revenue Growth, Stalled Profit: The Cost of Integration

earnings · pharma · acquisition

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
TORNTPHARMTORRENT PHARMACEUTICALS LTD.

Strong growth masked by margin pressure; semaglutide setback derails targets

JB integration · cost synergies · semaglutide supply

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
DRREDDYDR.REDDY'S LABORATORIES LTD.

Base Holds, But Semaglutide Stumble Masks the Strength

semaglutide recovery · abatacept approval · base business growth

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
DRREDDYDR.REDDY'S LABORATORIES LTD.

Base business solid, semaglutide stumble masks underlying strength

semaglutide recovery · abatacept pathway · emerging markets growth

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
INDSWFTLABIND-SWIFT LABORATORIES LTD.

When Pharma Capex Unlocks Regulated Markets: Ind-Swift's EU-GMP Bet

pharma capex · EU-GMP certification · regulated markets

ResearchDeep dive6 minPharma & Healthcare
MANIPALHOSLLOYDSENGG+6

When Consolidation Meets Opportunity—The August M&A Burst Across Infra, Healthcare, and Manufacturing

M&A · consolidation · strategic acquisitions

ResearchDeep dive6 minIndustrials & Infra
17 Aug 2026
FREDUNFredun Pharmaceuticals Ltd

The 90% Quarter That Rewrites 30% Growth

earnings · growth · guidance

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
FREDUNFredun Pharmaceuticals Ltd

Strong Q1 delivery with raised FY27 guidance; margin timeline uncertain

revenue growth · new-age brands · geographic expansion

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
ZIMLABZim Laboratories Ltd

Best quarter in years masks a loss-making quarter; EU bet remains unproven

EU-GMP reinstatement · loss-making growth · margin compression

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
ZIMLABZim Laboratories Ltd

Loss-making quarter masks EU-GMP bet; profitability path unproven

EU-GMP remediation · NIP/OTF pipeline · regulated markets

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
LUPINLUPIN LTD.

Lupin's CNS Anchor—When Pitolisant Approval Meets Competitive Generic Density

USFDA approval · Pitolisant · CNS drugs

ResearchDeep dive5 minPharma & Healthcare
WINDLASWindlas Biotech Ltd

Record revenue, flat profit—the ESOP mask and the Plant 6 pivot

CDMO · Trade Generics · Plant 6

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
WINDLASWindlas Biotech Ltd

Record revenue, flat profit; Plant 6 catalyst ahead

14 consecutive quarters · CDMO 29% growth · TGx stagnant

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
AHCLAnlon Healthcare Ltd

The ₹87.6 Crore Growth Story That Isn't—Organic Anlon Is Flat

margin collapse · acquisition dependency · organic stagnation

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
AHCLAnlon Healthcare Ltd

Strong revenue beat, EBITDA miss; margin recovery critical

acquisition-led growth · margin pressure · raw material inflation

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
IPCALABIPCA LABORATORIES LTD.

Headline Beat, Organic Softer: Material Costs Rising

earnings beat · organic growth · material costs

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
IPCALABIPCA LABORATORIES LTD.

Beat Q1 sharply, FY27 guide raised 2-3pp; material costs rising

Revenue +21% · Guide raised · Biotech 7-pipeline

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
JAGSNPHARMJAGSONPAL PHARMACEUTICALS LTD.

Operations Shine, But Revenue Can't Hit the Full-Year Target at This Pace

earnings review · revenue guidance · Aequitas acquisition

Result verdictFollow-upQ1 FY276 minPharma & Healthcare
JAGSNPHARMJAGSONPAL PHARMACEUTICALS LTD.

Growth soft vs guidance; Aequitas entry strategic but margins thin

brand_led_growth · semi_chronic_shift · aequitas_acquisition

TranscriptDeep diveQ1 FY276 minPharma & Healthcare
GPTHEALTHGPT Healthcare Ltd

YoY beat, but momentum stumbles — Raipur loss and sequential decline raise execution concerns

earnings review · sequential weakness · Raipur profitability

Result verdictFollow-upQ1 FY276 minPharma & Healthcare